Garfish, which are found in the Indo-Pacific Ocean areas,
Introduction
Injuries caused by ocean-dwelling creatures are usually considered to be rare and exotic. Such injuries, however, are an acknowledged occupational hazard for many people who catch fish from tropical seas. One species that causes considerable concern is the garfish. This paper documents some of the serious injuries caused by garfish in Papua New Guinea. Although little has previously been published about the dangers of garfish, they can be a greater threat than the shark, particularly to people fishing in coastal waters at night with the aid of a light.
The order Beloniformes includes several species of fish in the Indo-Pacific Ocean areas. They are known by various names, including garfish, needle-fish, long tom, alligator gar, and aiguille. They are surface predators, often congregating in large schools. Their bodies are long, tubular, and silver in colour (figure). Although they hunt close beneath the surface, they are so well camouflaged by countershading that they blend into the background.' Their slender, spear-like beak consists of two narrow jaws with small pointed teeth (figure) . One The external wound may appear deceptively trivial. It should be regarded as a stab wound and, therefore, the possibility of internal injury should be borne in mind. Patients speared in the chest or abdomen should be considered for urgent transfer to a hospital with surgical facilities. Little is known about ways of preventing injury by these fish, although placing canoes in a circle and spearing only fish in the central pool of light may lessen the risk.
Introduction Second-line drug treatment for rheumatoid arthritis is associated with considerable toxicity, which often prevents long-term treatment with a single agent.'-3 The disease may remain active for many years, and a sequence of second-line drugs may be needed. It is therefore important to establish the effect of order of administration of second-line drugs on the development of side effects and the efficacy of individual drugs. Results of previous retrospective studies on the effect of prior gold treatment on subsequent penicillamine treatment have been contradictory.4" We report a prospective study of patients who had stopped taking gold, penicillamine, or levamisole and were subsequently randomly allocated to one of the alternative drugs. 
Patients and methods
We studied 88 patients with classical or definite rheumatoid arthritis. All had stopped taking a second-line drug because of toxicity or lack of effect (38 had previously received gold, 19 penicillamine, and 31 levamisole). A further second-line drug was indicated because of progressive inflammatory disease, and after a "wash-out" period they were randomly allocated to one of the alternative drugs. The treatmentfree interval allowed was three months unless extremely active disease necessitated earlier introduction of a second or third drug. When results from concurrent studies in 123 patients showed that levamisole was less effective and more toxic than the other drugs3 levamisole was given only to patients who had stopped taking both gold and penicillamine.
No patient was receiving corticosteroids at the time of study, but all continued non-steroidal anti-inflammatory drugs and general supportive measures. Patients were encouraged to persist with the treatment for six months unless unacceptable side effects occurred. All patients continuing treatment were monitored fortnightly or monthly for a minimum of one year.
Sodium aurothiomalate (Myocrisin) was given intramuscularly as a 10 mg test dose followed by weekly injections of 50 mg until a response was achieved. Thereafter 50 mg injections were given fortnightly, then three-weekly and ultimately four-weekly. Penicillamine was started at a daily dose of 125 mg and increased by 125 mg at fortnightly or monthly intervals until response occurred or a maximum of 1000 mg daily was reached. Levamisole was given initially as 150 mg on three consecutive days weekly, but when results of multicentre studies became available this was reduced to 150 mg weekly. If patients failed to respond to the low dose after six months the dose was increased to 150 mg twice weekly and, if necessary, to 150 mg on three consecutive days. Patients stopped taking the drugs when any of the following occurred:
(1) Proteinuria greater than 300 mg/day when other causes had been excluded. If, when the proteinuria had settled, the patient agreed to a further trial reintroduction of the drug at a lower dose was tried. (2) Platelet count less than 150 x 109/1 or white cell count less than 4 x 109/1 on two consecutive occasions. In patients receiving penicillamine reintroduction of the drug at a dose of 125 mg was tried if the platelet count returned promptly to normal. (3) Rash, mouth ulceration, myalgia, or gastrointestinal upset and either the patient refused to try rechallenge at a lower dose or the side effect recurred when the drug was reintroduced. (4) Deterioration of arthritis and the patient was unwilling to persevere.
A third drug was given to 26 patients who had stopping taking two of the drugs and in whom continuing disease activity necessitated further second-line treatment.
Appropriate non-parametric statistics were used throughout'2 to test for significance.
